SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract

January 18, 2023

https://www.globenewswire.com/news-release/2023/01/18/2590857/0/en/SAB-Biotherapeutics-Receives-an-Additional-8-2-Million-in-Closeout-of-DoD-Contract.html

SIOUX FALLS, S.D., Jan. 18, 2023 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq:SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, high-avidity, fully-human polyclonal antibodies without the need for human donors, announced today that the company has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and development contract. This brings the total final closeout settlement to $16.8 million received since November 2022.

Read more at globenewswire.com

Related news for (SABS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.